I always appreciate different POVs on any stock, but across all my investment boards I have not read one this negative. Part of it I get, everyone is frustrated that AVXL did not start confirmatory trial sooner, and Missling is slow and not a good communicator and AVXL has gone to the well a few too many times vs finding a strong BP partner, etc. etc....but why are some posting 7-10x/day saying the same thing over and over?
It would be most helpful if a short (Doc or someone) would share a response to one question.... "What have you seen from all the results published to date that strongly suggests Blarcamesine is not effective even among the ABCLEASR3 cohort?" I get they will need another study to confirm and post-hoc analysis is not definitive, but what makes you believe a P3 targeting AB3 population would not show strong clinical efficacy?
Market Data 
Markets 
